{
    "ticker": "PTN",
    "name": "Palatin Technologies, Inc.",
    "description": "Palatin Technologies, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of various medical conditions. Founded in 1991 and headquartered in Cranbury, New Jersey, Palatin is dedicated to advancing its proprietary peptide-based drug discovery platform, with a strong emphasis on unmet medical needs. The company is well-known for its lead product candidates, including Vyleesi (bremelanotide), which is used for the treatment of hypoactive sexual desire disorder in premenopausal women. Palatin's research and development efforts are centered on exploring the physiological roles of the melanocortin system and its potential therapeutic applications in areas such as sexual health, obesity, and cardiovascular diseases. With a commitment to scientific innovation and patient care, Palatin strives to deliver novel treatment options that enhance the quality of life for patients. The company actively collaborates with research institutions and partners to expand its portfolio and accelerate the development of its drug candidates.",
    "industry": [
        "Biopharmaceuticals",
        "Healthcare"
    ],
    "headquarters": "Cranbury, New Jersey, USA",
    "founded": "1991",
    "website": "http://www.palatin.com",
    "ceo": "Carl Spana",
    "social_media": {
        "twitter": "https://twitter.com/palatintx",
        "linkedin": "https://www.linkedin.com/company/palatin-technologies"
    },
    "investor_relations": "http://www.palatin.com/investor-relations/",
    "key_executives": [
        {
            "name": "Carl Spana",
            "position": "CEO"
        },
        {
            "name": "Sharon Mates",
            "position": "Chairman"
        }
    ],
    "product_categories": [
        {
            "category": "Pharmaceuticals",
            "products": [
                "Vyleesi"
            ]
        }
    ],
    "seo": {
        "meta_title": "Palatin Technologies, Inc. | Biopharmaceutical Innovations",
        "meta_description": "Explore Palatin Technologies, a biopharmaceutical company focused on innovative therapies for unmet medical needs, including sexual health and obesity.",
        "keywords": [
            "Palatin Technologies",
            "Biopharmaceuticals",
            "Vyleesi",
            "Healthcare",
            "Melanocortin System"
        ]
    },
    "faq": [
        {
            "question": "What is Palatin Technologies known for?",
            "answer": "Palatin Technologies is known for its development of innovative therapies, particularly Vyleesi for hypoactive sexual desire disorder."
        },
        {
            "question": "Who is the CEO of Palatin Technologies?",
            "answer": "Carl Spana is the CEO of Palatin Technologies, Inc."
        },
        {
            "question": "Where is Palatin Technologies headquartered?",
            "answer": "Palatin Technologies is headquartered in Cranbury, New Jersey, USA."
        },
        {
            "question": "What are Palatin's main products?",
            "answer": "Palatin's main product is Vyleesi, a treatment for hypoactive sexual desire disorder."
        },
        {
            "question": "When was Palatin Technologies founded?",
            "answer": "Palatin Technologies was founded in 1991."
        }
    ],
    "competitors": [
        "AMGN",
        "REGN",
        "VRTX"
    ],
    "related_stocks": [
        "GILD",
        "BIIB",
        "JNJ",
        "PFE"
    ]
}